AiPharma Signs Heads of Agreement to Acquire a Controlling Interest in a Pharmaceutical Business with Global Innovation, Manufacturing, Distribution Footprint, and Revenues in Excess of $450 Million
The transaction is a strategic opportunity to position Cellvera as a fully integrated biotech innovation company
Delaware, USA – December 1st, 2021 – Cellvera Global Holdings LLC (“Cellvera” or the “Company”) has signed a Heads of Agreement with an international pharmaceutical business to acquire a controlling interest. Cellvera is a company focused on discovering, developing and commercializing antiviral therapies across a broad spectrum of infectious diseases. Cellvera holds directly, or through its affiliates, worldwide (excluding Japan) exclusive rights to Avigan (Favipiravir) a broad spectrum oral antiviral treatment that targets COVID-19 and 11 other classes of infectious diseases.
The potential acquisition presents an opportunity to accelerate Cellvera’s key innovation, operation, and commercialization goals starting in early 2022 as follows:
• Expansion to an existing portfolio of innovative molecules
• Integration of global manufacturing capabilities into current operational infrastructure
• Global distribution network offering additional channels for AiPharma’s current and future products
• Compelling financial profile, the target acquisition has diversified annual revenues in excess of $450M USD
“This proposed transaction has the potential to accelerate Cellvera’s overall business goals and its ability to develop and commercialize new molecules and drugs at a more rapid pace. We look forward to advancing this opportunity that allows us to execute on our strategy of growth, global expansion and product portfolio diversification, creating long-term value for investors and stakeholders.” stated Dr. Alessandro Gadotti, CEO Cellvera Group.
Cellvera has secured a commitment up to 650M USD from a multi-family office for the funding of this acquisition.
The acquisition and the relative funding is subject to confirmatory due diligence, entry into a definitive agreement based on agreed terms and other closing conditions, including regulatory, board and shareholder approvals.
Cellvera is a biopharmaceutical company focused on discovering, developing, and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleotide chemistry, biology, biochemistry, and virology, Cellvera has built a nucleotide prodrug platform to develop novel product candidates to treat
single-stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases.
Currently, Cellvera is focused on the clinical and commercial development of orally available, potent, and selective nucleotide prodrugs for
difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). Cellvera also holds exclusive commercial rights for Avigan in Russia and China.
For more information, please visit www.aipharmalab.com.
We enable the acceleration of life science research
and development in the pursuit of improved human health